All In Biotech

Drug Trial Radar · NCT02304393

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

An Open-Label, Multicenter, Dose-Escalation Phase IB Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of Selicrelumab (CD40 Agonist) in Combination With Atezolizumab (Anti PD-L1) in Patients With Locally Advanced and/or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

140

Actual

Start

Dec 12, 2014

Primary completion

Nov 7, 2019

Study completion Nov 7, 2019

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 1, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics and activity of Selicrelumab administered in combination with Atezolizumab (ATZ) in participants with metastatic or locally advanced solid tumors. The study will be conducted in two Parts (I and II), with Part I divided into Parts IA and IB. All participants will be followed up for survival until death or loss of follow-up after the last visit or withdrawal of consent.

Conditions

  • Solid Tumors

Interventions

  • AtezolizumabDrug

    Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.

  • SelicrelumabDrug

    Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part IA: Percentage of Participants with Adverse Events and Serious Adverse EventsTime frame: Baseline up to 28 Days After the Last Dose (Approximately 38 Months)
  2. Part IB: Percentage of Participants with Adverse Events and Serious Adverse EventsTime frame: Baseline up to 28 Days After the Last Dose (Approximately 38 Months)
  3. Part IB: Percentage of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 Day 1 up to Cycle 2 Day 2 (Cycle length = 21 days)
  4. Part IB: Maximum Tolerated Dose (MTD) of SelicrelumabTime frame: Cycle 1 Day 1 up to Cycle 2 Day 2 (Cycle length = 21 days)
  5. Part IB: Recommended Part II Dose of SelicrelumabTime frame: Cycle 1 Day 1 up to Cycle 2 Day 2 (Cycle length = 21 days)
  6. Part II: Percentage of Participants with Adverse Events and Serious Adverse EventsTime frame: Baseline up to 28 days after the last dose (approximately 38 months)
  7. Part II: Percentage of Participants With Best Overall Response, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
  8. Part II: Progression-Free Survival (PFS), as Determined by Investigator Using RECIST Version 1.1Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
  9. Part II: Duration of Objective Response, as Determined by Investigator Using RECIST Version 1.1Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
  10. Part II: Percentage of Participants With Disease Control, as Determined by Investigator Using RECIST Version 1.1Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
  11. Part II: Percentage of Participants With Disease Control, as Determined by Investigator Using Unidimensional irRCTime frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
  12. Part II: PFS, as Determined by Investigator Using Unidimensional irRCTime frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
  13. Part II: Percentage of Participants With Best Overall Response, as Determined by Investigator Using Unidimensional Immune-Related Response Criteria (irRC)Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
  14. Part II: Duration of Objective Response, as Determined by Investigator Using Unidimensional irRCTime frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 38 months)
  15. Part II: Overall SurvivalTime frame: Baseline up to death due to any cause (up to approximately 38 months)

Locations

11 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University Health Network; Princess Margaret Hospital; Medical Oncology Dept

    Toronto, Ontario, Canada

  • Jewish General Hospital / McGill University

    Montreal, Quebec, Canada

  • Rigshospitalet; Onkologisk Klinik

    København Ø, Denmark

  • Aphm; Cpcet

    Marseille, France

  • Hopital Saint Louis, Service D Oncologie Medicale

    Paris, France

  • Institut Gustave Roussy; Sitep

    Villejuif, France

  • Antoni van Leeuwenhoek Ziekenhuis

    Amsterdam, Netherlands

  • Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed

    Rotterdam, Netherlands

  • Hospital Univ Vall d'Hebron; Servicio de Oncologia

    Barcelona, Spain

  • START Madrid. Centro Integral Oncologico Clara Campal; CIOCC

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.